Preventive Vaccines Market in Europe 2020-2026: COVID-19 Impact and Growth Opportunity - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% annually over 2020-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.

Highlighted with 61 tables and 52 figures, this 140-page report "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" is based on holistic research of the entire European preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides an estimate/forecast from 2020 till 2026 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Five Forces

Based on Vaccine Type, the European market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.

• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the European market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.

• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases

Based on Administration, the European market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.

• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

Based on Patient, the European market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.

• Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
• Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into the Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in the European preventive vaccines market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics

3 Segmentation of Europe Market by Vaccine Type

4 Segmentation of Europe Market by Disease

5 Segmentation of Europe Market by Administration

6 Segmentation of Europe Market by Patient

7 European Market 2020-2026 by Country

8 Competitive Landscape

9 Investing in Europe Market: Risk Assessment and Management

Key Companies Mentioned

• AstraZeneca plc
• Bavarian Nordic A/S
• China National Biotec Group Company Ltd.
• CSL Ltd.
• Daiichi Sankyo Co. Ltd
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co.
• Moderna Inc.
• Novavax, Inc.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/chard4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900